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88 Determination of patient screen failure and dropout rates for
industry-sponsored CF inhaled antibiotic studies
V. Brandi1. 1Quintiles, Miami, United States
Objectives: A CRO’s remit is to review sponsor’s protocols and assumptions as
part of the RFPprocess. A key element inﬂuencing study success is to determine
if realistic screen failure (SFR) and dropout rates (DOR) have been used. If either
is unrealistic it can result in an under-powered study (subsequently leading to
erroneous conclusions), budget overruns and/or timeline extensions.
Methods: Quintiles’ proprietary databases, journal articles and the FDA’s Sum-
mary Basis of Approval documents were reviewed to determine SFR and DOR
for industry-sponsored CF inhaled antibiotic studies. For three pivotal placebo-
controlled studies, sites randomized a mean of 15.4 patients/site (range: 13.3–29.6).
Two of the three pivotal studies had a similar SFR (41.9 and 39.1%); the other study
experienced a much lower SFR (6.4%). This study enrolled many young patients
and was conducted in different geographical regions than the other two studies
and it is unclear of how this may have inﬂuenced this metric. DOR at the end of
the treatment period were very similar and ranged from 15.7 to 18.8%. It is not
surprising that the two studies with a post-treatment follow up period experienced
an overall high DOR (39.9 and 24.4%). The SFR and DOR for both open label
studies were similar despite the difference in study length.
Conclusions: It is imperative to review data in order to adequately project key
metrics such as SFR and DOR. These can be affected by entry criteria, study
design and duration. It is important to select a study similar to the protocol under
review to avoid common pitfalls such as underestimating the amount of patients
likely to complete the entire study.
89 Evaluation of a twice daily tobramycin regimen in adult cystic
ﬁbrosis patients
D. McCabe1, H.C. Rodgers1. 1NHS Lothian, Scottish Adult Cystic Fibrosis Service,
Edinburgh, United Kingdom
Objectives: The aims of this study were:
1. Improve the proportion of patients achieving target serum concentrations of
intravenous tobramycin therapy on ﬁrst dose selection.
2. Reduction in number of dose adjustments and invasive blood tests.
3. Ensure comparable efﬁcacy and safety.
Methods: Two Tobramycin regimens were compared:
• “Standard” regimen: 10mg/kg/day split three times daily given by IV bolus
injection, serum concentrations (pre-dose and 1 hour post dose) were sampled
after the third dose.
• Twice daily regimen: 120mg/m2 12 hourly, based on body surface area (BSA)
given by IV bolus injection, serum concentrations were determined on the second
dose.
In both cases doses were adjusted to achieve target concentrations of pre-dose
<2mg/L and one hour post-dose 8−12mg/L. Serum concentrations were rechecked
after 7 days or after any dose adjustment (n = 31).
Tobramycin was prescribed for Pseudomonal infective exacerbations determined
on clinical assessment, with other a beta-lactam, according to local CF antibiotic
guidelines for at least 2 weeks.
Primary outcome measure was proportion of patients’ achieving target concentra-
tions. Secondary outcomes were creatinine clearance, change in FEV1, number of
dose adjustments and numbers of blood tests.
Conclusion: There was a signiﬁcant improvement in the proportion of patients
achieving target concentration on the new regimen (p< 0.001). Number of blood
tests and dose adjustments were signiﬁcantly reduced (p = 0.01). Change in FEV1
was similar for both regimens (p = 0.8). In conclusion, a twice daily regimen based
on BSA was safe and effective for the treatment of pseudomonas exacerbations in
Adult CF patients.
90 Inhalation of colistimethate dry powder (Colobreathe) results in
negligible systemic exposure
J. Riethmueller1,2, M. Goldman3, P. Turay3. 1University Children’s Hospital,
Paediatric Pneumologie, Tuebingen, Germany; 2Center for Pediatric Clinical
Studies, Paediatric Pneumonologie, Tuebingen, Germany; 3Forest Laboratories
UK Ltd, Medical, Dartford, United Kingdom
Objective: To evaluate the systemic absorption of Colobreathe, colistimethate dry
powder for inhalation (CDPI) in CF subjects with chronic pulmonary infection with
P. aeruginosa (PA).
Methods: After 72 hr washout, 34 subjects aged 6−60 yrs received 1.6625 IU CDPI
twice daily for 7 days. Blood, urine and sputum were assayed using LC-MS/MS
methodology.
Results: Maximum plasma concentration (Cmax) for total CMS was achieved
between 0.5 and 1 hr post dose. Mean peak plasma Cmax for total CMS after
the ﬁnal dose was 256.8 (±106.0), 321.2 (±179.8) and 455.9 (±314.4) ng/ml
for age groups 6−12 yrs, 13−17 yrs, 18+ yrs respectively. Corresponding levels
for free colistin were 36.2 (±19.7) ng/ml, 35.6 (±21.5) ng/ml and 52.4 (±39.9)
ng/ml. The mean sputum CMS concentrations after 7 days therapy were respectively
119.1 (±88.1) 272.1 (±226.1) and 126.8 (±88.5) mg/l. Urinary excretion of CMS
was <3% of the administered dose. The AUC0−6 and the dose adjusted AUC0−6
(AUC0−6/D) for total CMS were similar between children and adolescents, while
higher AUC0−6 was observed in the adult group. When AUC0−6 was adjusted by
dose and body weight, a slightly higher AUC0−6/D/W for total CMS was observed
in children. High PK variability was observed in all age groups. Comparison of
results versus an established legacy microbiological assay showed that this method
lacked precision and sensitivity.
Conclusion: Inhalation of CDPI results in very low levels of systemic drug. This
suggests limited potential for drug-drug interaction. Sputum levels are well in
excess of the systemic breakpoint of PA. The predominant species is CMS and
may signiﬁcantly contribute to the therapeutic effect rather than colistin.
91 Sequential inhalative tobramycin–colistin-combination stabilizes
patients with chronic Pseudomonas aeruginosa colonization
G. Herrmann1, D. Hellwig2, H.-E. Heuer3, S. Heyder4, H. Ko¨ster5, K. Kro¨ger6,
K. Paul7, U. Mellies8, A. Schmitt9, D. Wagenseil9, J. Riethmueller1. 1University
Children’s Hospital, Tuebingen, Germany; 2University Hospital Freiburg, Freiburg,
Germany; 3Cf Ambulance, Hamburg, Germany; 4Klinik Schillerho¨he, Gerlingen,
Germany; 5Klinikum Oldenburg, Oldenburg, Germany; 6Luisenhospital Aachen,
Aachen, Germany; 7Cf Ambulance, Berlin, Germany; 8University Hospital Essen,
Essen, Germany; 9Chiesi GmbH, Hamburg, Germany
Pseudomonas aeruginosa in the airways of CF-patients restricts the efﬁcacy of
antibiotics leading to chronic infections which have a large impact on morbidity
and mortality. Antibiotic combination therapy might be more efﬁcient than single
antibiotics to combat lung infections in CF.
Methods: In an observational study 40 CF patients, suffering from chronic
P. aeruginosa lung infection, pretreated either with Tobramycin or Colistin, were
inhalatively treated three times (28 days each) with 300mg Tobramycin (Bramitob®)
twice daily followed by Colistin (1 Mio I.U.) twice daily. Lung function expressed as
expiratory volume in 1 sec (FEV1), bacterial resistance, QoL and clinical outcome
were determined before, after 2 cycles and after the study.
Results: Interim analysis in 22 of 40 patients (mean age 22.9±10.2 years) showed
that drugs were well tolerated by almost all patients (80%). FEV1 increased
(+3.4±13.7% absolute, +8.6±23% relative to baseline; p = 0.14. Without exacer-
bative patients +2.9±5.6% absolute and +6.4±11% relative to baseline; p = 0.028),
coughing and sputum was reduced in >50% of patients and therapeutic outcome
increased in 82% of patients detected by clinical assessment of physicians. Exacer-
bations rates were reduced by 44% (p = 0.13) and iv-treatments were also reduced
by 40% (p = 0.008). Resistances against antibiotics increased from 11% to 21%.
Conclusion: The efﬁcacy of tobramycin and colistin sequentially combined, sug-
gest that combination therapy is more efﬁcient than single antibiotic therapy to
combat lung infection of P. aeruginosa in CF patients. Alternative combinations of
inhalative antibiotics should be investigated in further trials.
